- $261.42bn
- $288.76bn
- $58.74bn
Brief: AstraZeneca Says Enhertu Recommended For EU Approval For Early Breast Cancer
Klygefa recommended for EU approval by CHMP
Enhertu recommended for approval in EU in early BC
Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs
Brief: Astrazeneca Says Klygefa Recommended For EU Approval To Treat Adults With Generalized Myasthenia Gravis
Director/PDMR Shareholding
Brief: AstraZeneca's Efzimfotase alfa Granted Priority Review In U.S.
AstraZeneca-Daiichi breast cancer drug cleared for NHS use in England
UK Stocks-Factors to watch on September 17 (updated)
UK Stocks-Factors to watch on September 17
AstraZeneca invests nearly $30 million to upgrade base in China
Press Digest: Financial Times - September 17
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Director/PDMR Shareholding
Director/PDMR Shareholding
Europe Research Roundup: GSK, Schott Pharma, Vodafone
UK Stocks-Factors to watch on September 14 (updated)
Live Markets: Before the bell: Europe softer as oil climbs, tech drags
Update on SERENA-4 Phase III trial